Adma Biologics (ADMA) Change in Cash (2011 - 2026)

Adma Biologics (ADMA) has 13 years of Change in Cash data on file, last reported at $26.2 million in Q4 2025.

• Quarterly Change in Cash rose 59.64% year-over-year to $26.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$15.5 million (down 129.96% YoY) and the FY2025 annual result came in at -$15.5 million, down 129.96% from the prior year.
• Change in Cash climbed to $26.2 million in Q4 2025, from -$28.9 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $51.6 million in Q4 2022 to a low of -$31.5 million in Q1 2025.
• A 5-year average of $1.6 million and a median of -$3.8 million in 2024 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2024 — Change in Cash jumped 741.44% — and 2025, when it sank 1780.29%.
• Tracing ADMA's Change in Cash over 5 years: stood at $16.7 million in 2021, then jumped by 209.48% to $51.6 million in 2022, then tumbled by 144.18% to -$22.8 million in 2023, then soared by 172.09% to $16.4 million in 2024, then soared by 59.64% to $26.2 million in 2025.
• The last three Change in Cash figures came in at $26.2 million (Q4 2025), -$28.9 million (Q3 2025), and $18.7 million (Q2 2025), per Business Quant data.